The present invention relates to a pharmaceutical oral fixed dose combinationcomprising a) a therapeutically effective amount of Aliskiren, or a pharmaceuticallyacceptable salt thereof, b) a therapeutically effective amount of Valsartan,or a pharmaceutically acceptable salt thereof, wherein the pharmaceuticaloral fixed dose combination shows an in vitro dissolution of component a) of 80%or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profileof component b) of 25% or more after 30 minutes, and 40% or more after 60 minutesat pH 4.5.
